Edition:
United States

Leap Therapeutics Inc (LPTX.OQ)

LPTX.OQ on NASDAQ Stock Exchange Global Market

6.77USD
15 Dec 2017
Change (% chg)

$0.10 (+1.50%)
Prev Close
$6.67
Open
$6.66
Day's High
$6.78
Day's Low
$6.65
Volume
5,647
Avg. Vol
8,984
52-wk High
$10.10
52-wk Low
$4.94

Select another date:

Fri, Dec 8 2017

BRIEF-Leap Therapeutics Files For Resale Of Up To 3.73 Mln Shares Of Co's Common Stock By Selling Stockholders

* LEAP THERAPEUTICS INC FILES FOR RESALE OF UP TO 3.73 MILLION SHARES OF CO'S COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING Source text: (http://bit.ly/2jdjIfs) Further company coverage:

BRIEF-Eli Lilly And Co reports 17.5 pct passive stake in Leap Therapeutics ‍​as of Nov 14

* Eli Lilly And Co reports 17.5 percent passive stake in Leap Therapeutics Inc‍​ ‍​as of November 14 - SEC Filing Source text: (http://bit.ly/2BcO2L7) Further company coverage:

BRIEF-Leap Therapeutics announces $18 million private placement offering

* Upon closing of transaction, leap will sell 2.96 million shares of unregistered common stock​

BRIEF-Leap Therapeutics qtrly loss per share $0.73

* Leap Therapeutics reports third quarter 2017 financial results and announces first patient dosed with DKN-01 and Keytruda® (pembrolizumab) in esophagogastric cancer trial

BRIEF-Leap Therapeutics announces collaboration with EORTC

* Leap Therapeutics announces collaboration with EORTC to evaluate DKN-01 in combination with PD-l1 cancer immunotherapy and chemotherapy in esophagogastric and biliary tract cancers

BRIEF-Leap Therapeutics says Q2 loss per share $0.74

* Q2 loss per share $0.74 - SEC filing Source text for Eikon: Further company coverage:

BRIEF-Leap Therapeutics Q2 net loss $6.9 mln vs $7.5 mln, a year earlier

* Leap therapeutics reports second quarter 2017 financial results

BRIEF-Leap Therapeutics says Merck will sponsor and fund initial trials of their combo drug study

* Leap Therapeutics - under agreement with unit of Merck, Co to sponsor and fund phase i/ii clinical trials of combination of dkn-01 and keytruda(reg)

BRIEF-Leap Therapeutics announces collaboration with Merck

* Leap therapeutics announces collaboration with merck to evaluate keytruda® (pembrolizumab) in combination with dkn-01 in esophagogastric cancer

Select another date: